Abstract

Phase I trials in patients with colon and breast cancer using the anti-LeY solid tumors with immunotoxin LMB-9 are being carried out in collaboration with Dr. Robert Kreitman. LMB-9 is a stable recombinant immunotoxin produced by genetic engineering. Also Dr. Robert Kreitman has completed a Phase I trial on leukemias and lymphomas with immunotoxin LMB-2 [anti-Tac(Fv)-PE38] that targets the alpha subunit of the IL2 receptor. In this trial, 1 complete response and many partial responses were observed. A Phase II trial is being planned. A clinical lot of an immunotoxin (BL22) that targets CD22 present on B-cell malignancies has been produced, and a Phase I trial is ongoing supervised by Dr. Kreitman. This immunotoxin has extremely good activity. Many complete responses have been observed in Hairy Cell Leukemia.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC010020-06
Application #
6559286
Study Section
(LMB)
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2001
Total Cost
Indirect Cost

  Institution

Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code

  Publications

Du, Xing; Beers, Richard; Fitzgerald, David J et al. (2008) Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res 68:6300-5
Onda, Masanori; Beers, Richard; Xiang, Laiman et al. (2008) An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A 105:11311-6
Sampson, John H; Akabani, Gamal; Archer, Gerald E et al. (2008) Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 10:320-9
Sampson, John H; Brady, Martin L; Petry, Neil A et al. (2007) Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery 60:ONS89-98;discussion ONS98-9
Sampson, John H; Raghavan, Raghu; Brady, Martin L et al. (2007) Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol 9:343-53
Sterman, Daniel H; Recio, Adri; Carroll, Richard G et al. (2007) A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 13:4456-66
Sampson, John H; Raghavan, Raghu; Provenzale, James M et al. (2007) Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. AJR Am J Roentgenol 188:703-9
Ise, Tomoko; Kreitman, Robert J; Pastan, Ira et al. (2006) Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera. Clin Chem Lab Med 44:594-602
Onda, Masanori; Nagata, Satoshi; Ho, Mitchell et al. (2006) Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 12:4225-31
Hassan, Raffit; Remaley, Alan T; Sampson, Maureen L et al. (2006) Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 12:447-53

Showing the most recent 10 out of 19 publications